Mathematical Modeling of Immuno-radioprotector Delivery System Using a Monoclonal Antibody

Abstract

Amifostine (WR-2721, delivered as Ethyol) is a radioprotector agent that reduces the likelihood of early and/or late biological effects by eliminating free radical particles during ionizing radiation fraction (radiotherapy). It activates in under normal tissues conditions to reduce mutation and fraction in DNA. Among 4000 prodrug compounds, amifostine is the only agent has been approved from the US Food and Drug Administration in clinical purposes. The main effective mechanisms of amifostine are based on scavenging for free radical, improving for DNA repair step and indication of cellular hypoxia. In the same time, this drug is not widely used around the world for different reasons mainly its high cost and toxicity level (lethal dose). Conjugating a monoclonal antibody with amifostine by a suitable linker is a process of Antibody Drug Conjugate producing immuno-radioprotector molecule hypothesis. Administrated molecule is an approach of targeted delivery therapy that increases the dosage uptake into particular area of treatment to minimize the dose distribution in non-targeted area in the body. In the present work, we proposed a three-compartment system model to simulate the two-pore theory pathway of an immuno-radioprotector molecule when it is crossing the physiological barriers. The model investigated its distribution and elimination in porous media (with both large and small pores) within a pharmacokinetics compartmented model approach.